Please use this identifier to cite or link to this item:
|Title:||Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants||Authors:||Forsyth, Cecily J ;Trotman, J.;Fournier, M;Lamy, T.;Seymour, J.F.;Sonet, A.;Janikova, A.;Shpilberg, O.;Gyan, E.;Tilly, H.;Estell, J.;Decaudin, D.;Fabiani, B.;Gabarre, J.;Salles, B.;Van Den Neste, E.;Canioni, D.;Garin, E.;Fulham, M.;Vander Borght, T.;Salles, G.||Issue Date:||Aug-2011||Source:||Volume 29, Issue 23, pp. 3194 - 3200||Journal title:||Journal of clinical oncology : official journal of the American Society of Clinical Oncology||Abstract:||PURPOSE: The utility of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. PATIENTS AND METHODS: Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. RESULTS: Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P < .001). Patients remaining PET positive had a significantly (P < .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). CONCLUSION: [(18)F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1240||DOI:||10.1200/jco.2011.35.0736||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/21747087||ISSN:||0732-183x||Publicaton type:||Journal Article||Keywords:||Drug Therapy||Study or Trial:||Randomized Controlled Clinical Trial/Controlled Clinical Trial|
|Appears in Collections:||Haematology|
Show full item record
checked on Jan 27, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.